TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03021603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets.
Study: NCT03723798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Low dose
Description: 3 tablets b.i.d for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 Mid dose
Description: 3 tablets b.i.d for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 High dose
Description: 3 tablets b.i.d for 12 weeks
Study: NCT02014831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study: NCT03723798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets b.i.d for 12 weeks
Study: NCT03351868

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene-modified autologous stem cells
Description: Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
Study: NCT02351492

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy and intraoperative cholangiography
Description: Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnet resonance cholangio-pancreaticography
Description: Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnet resonance imaging
Description: Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter
Description: Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
Study: NCT02535013

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound with appropriate interventions depending on the ultrasound finding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound with appropriate interventions depending on the ultrasound finding
Study: NCT02807220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imuneks 10mg
Description: Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
Study: NCT03441529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Description: Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Description: Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
Study: NCT02081508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference onset
Description: Temporal duration of interference onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference onset
Description: Temporal duration of interference onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference onset
Description: Temporal duration of interference onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference onset
Description: Temporal duration of interference onset.
Study: NCT02370368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XBOX Kinect Just Dance 2014
Description: The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Agility Ladder Drills
Description: Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
Study: NCT00735553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: Two 25 mg mg capsules of Proellex® orally daily for up to four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules orally daily for up to four months
Study: NCT04462029

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
Study: NCT02014831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study: NCT04462029

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Study: NCT02014831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIP
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study: NCT01635712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
Study: NCT02075554

Intervention type: DEVICE
Group type: OTHER
Intervention: CALIBER
Description: Expandable interbody spacer
Study: NCT01477268

Intervention type: DRUG
Group type: OTHER
Intervention: Zoloft (antidepressant)
Description: Zoloft 50-200 mg po od x 12 weeks
Study: NCT00117026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for benfotiamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: 300mg/day
Study: NCT02523716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxia
Description: Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
Study: NCT03647241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Ligating Brackets
Description: These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Ligating Brackets
Description: These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditionally-Ligated Brackets
Description: These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
Study: NCT04221828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Description: NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
Study: NCT03877198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen control by the CLiO2 algorithm
Description: Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen control by the Oxygenie algorithm
Description: Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
Study: NCT02448576

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation
Description: Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
Study: NCT03697707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: allogeneic dendritic cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: allogeneic dendritic cell vaccine
Study: NCT03689920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Description: The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Description: The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
Study: NCT00914589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Study: NCT00455650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine
Description: A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine
Description: A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
Study: NCT01407458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper Limb Exercises
Description: Upper limb exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal physical exercises
Description: Exercises usually done by children in physical education classes
Study: NCT02934789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic myomectomy with Truclear
Description: Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
Study: NCT01557985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
Study: NCT03728764

Intervention type: OTHER
Group type: OTHER
Intervention: Preterm infant formula
Description: Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
Study: NCT02988089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility dependant strategy
Description: Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )
Description: Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.

Intervention type: DRUG
Group type: OTHER
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.
Study: NCT04465773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia for scheduled gynecological surgery
Study: NCT04462029

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water

Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Study: NCT01431898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match GS-9669 tablet